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Abstract: word count=252 (limit 275)  
Background and Aims: Liver transplantation is a successful treatment for patients with liver 
failure. However, organ shortage results in over 11% of patients losing their chance of a 
transplant due to liver decompensation and death. Ischemia/reperfusion injury (IRI) following 
conventional cold storage (CS) is a major cause of injury leading to graft loss after liver 
transplantation. A novel method of organ preservation, normothermic machine perfusion 
(NMP), provides oxygen and nutrition during preservation and allows aerobic metabolism. 
NMP has recently been shown to enable improved organ utilization and post-transplant 
outcomes following a Phase I and a Phase III randomized trial. The aim of the present study 
is to assess the impact of NMP on reducing IRI and to define the underlying mechanisms.  
Methods: We transplanted and compared 12 NMP with 27 CS-preserved livers by 
performing gene microarray, immunoprofiling of hepatic lymphocytes and immunochemistry 
staining of liver tissues for assessing necrosis, platelet deposition and neutrophil infiltration, 
and the status of steatosis after NMP or CS pre- and post-reperfusion.  
Results: Recipients receiving NMP grafts showed significantly lower peak AST levels than 
those receiving CS grafts. NMP altered gene-expression profiles of liver tissue from pro-
inflammation to pro-healing and regeneration. NMP also reduced the number of IFN- and 
IL-17 producing T cells and enlarged the CD4posCD25highCD127negFOXP3pos Treg pool. 
NMP liver tissues showed less necrosis and apoptosis in the parenchyma and fewer 
neutrophil infiltration compared to CS liver tissues. 
Conclusion: Reduced IRI in NMP recipients was the consequence of the combination of 
inhibiting inflammation and promoting graft regeneration.  
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Introduction 
Liver transplantation is the only treatment for patients with end-stage acute and chronic 
liver failure. It is a successful treatment with a 5-year patient and graft survival rate 
exceeding 80% (NHS BT report 2016 to 2017). However, organ shortage remains a global 
problem that results in the removal of over 11% of patients placed on the waiting list due to 
death or worsening of their condition (1). 
The rate of organ donations has increased over the last 10 years. However, this increase 
is mainly limited to high-risk, so-called ‘marginal donors’, which largely comprise donors 
deceased after circulatory death (DCD) (2) older donors,  and fatty livers (3).  There is 
evidence that marginal organs have greater vulnerability to ischemia reperfusion injury (IRI), 
an inevitable process of organ transplantation (4). 
A number of experimental and clinical studies have shown that reperfusion of allografts 
is associated with organ inflammation characterized by the release of inflammatory 
mediators, up-regulation of adhesion molecules, immune cell infiltration and increased cell 
death (5–7). This damage affects short and long-term organ outcome by contributing to the 
development of primary non-function and ischemic cholangiopathy respectively (8). 
Normothermic machine perfusion (NMP) is a novel technology that allows preservation 
and transport of organs from donor hospital to recipient hospital at body temperature while 
providing the organ with oxygen and nutrients (9). NMP has been introduced into clinical 
practice with the aim of minimizing IRI and its effects on the liver graft, enabling successful 
preservation and functional testing of marginal livers, improving the logistics of 
transplantation by allowing prolonged preservation from 12 to 24 hours, and ultimately 
increasing the number of livers successfully transplanted. A phase I clinical trial using a 
novel NMP device (metra®, OrganOx Ltd, UK) demonstrated safety of the technology (10).  
The NMP device also led to a reduction in the levels of liver enzyme aspartate 
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aminotransferase (AST) in the recipients, which is used as a surrogate marker of liver damage 
(10). The reduction in allograft damage and improved organ utilization of NMP over CS has 
been further confirmed in a randomized controlled multicenter trial including seven liver 
transplant centers from the UK and Europe (Consortium for Organ Preservation in Europe, 
COPE, www.cope-eu.org), in which a total of 137 NMP and 133 cold storage (CS) grafts 
were enrolled (11), with 120 NMP and 100 CS livers ultimately transplanted. 
The current investigation aims to assess the impact of NMP preservation on the degree 
of liver allograft IRI compared to conventional CS, and to identify the mechanisms 
underpinning any observed differences.  
 
Material and Methods 
DONORS AND RECIPIENTS 
In 2013, we carried out 14 liver transplants using DBD (n = 12) and DCD (n = 2) grafts 
preserved with NMP, as part of a phase I clinical trial that recruited a total of 20 patients (10). 
In the current analysis, we included only the 12 DBD grafts and excluded the DCD 
transplants due to the small number. These livers were matched with 27 CS DBD grafts that 
were transplanted in the same period.  Donors and recipients in both groups were matched 
according to age, intensive therapy unit (ITU) stay, infections, inotropic support and donor 
liver steatosis. The recipients were also matching for their original liver diseases, with a 
similar proportion of alcoholic related liver diseases, autoimmune liver diseases (autoimmune 
hepatitis, primary sclerosing cholangitis and primary biliary cholangitis), HCV infection, 
HCC, inherited hepatic cholestasis and drugs induced acute liver failure [paracetamol 
overdose (POD) and non-POD], they also presented with a similar severity of liver disease, 
representing by MELD scores assessed at the time listing for liver transplant. Their 
demographic and clinical data were summarized in Tables 1 and 2 (Table 1 for donors and 
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Table 2 for recipients respectively). This study was approved by the Ethics Committees of St 
Thomas’s Hospital (REC Reference: 09/H0802/100) and Dulwich Ethics Committee  
Approvals were also obtained from National Health Service Blood and Transplant (NHSBT), 
National Research Ethics Committee, and the Medicines and Healthcare Products Regulatory 
Authority. The trial was registered with the ISRCTN (14355416) 
LIVER PERFUSATE AND ISOLATION OF HEPATIC MONONUCLEAR CELLS 
(HMC)  
We previously showed that intrahepatic lymphocytes (HMC) obtained through liver perfusion 
are representative of liver-resident lymphocytes (12). Donor livers were perfused at the end 
of NMP or CS with preservation solution as previously described (10). In brief, in NMP the 
perfusion was stopped at the end of preservation and the organ was cooled by rapid flashing 
of 2 liters of cold HTK solution (Custodiol-HTK, Essential Pharmaceuticals, Ewing, NJ) 
(10). An additional 1 liter was used to further flush the grafts and the clear perfusate was 
collected for mononuclear cell extraction. In CS livers, grafts were perfused with 1 liter of 
UW solution at the end of preservation and the perfusate was similarly collected.  All 
perfusates were processed within 6 hours by centrifugation to reduce the volume. The final 
volume of 30 ml of HMC rich solution was used to isolate HMC by density gradient 
centrifugation (Lymphoprep, GE, Sweden) (12).  HMC isolated after NMP (8 out of the 12 
cases) were compared to those after CS (20 out of 27 grafts).  
PHENOTYPIC AND FUNCTIONAL ANALYSIS OF HMC USING FLOW 
CYTOMETRY 
HMCs were stained for 20 min at 4°C degree using monoclonal antibodies (mAbs) 
specific for CD3-PE-Cy7, CD4-APC-Cy7, CD8-PercP-Cy5.5, CD19-APC, CD25-PE, 
 7 
CD127-FITC (Cambridge, UK) and FOXP3-FITC (eBioscience, San Diego, USA). For 
intracellular cytokine detection HMC were stimulated with  PMA/Ionomycin/Brefeldin 
(eBioscience) for 4 hours, fixed (Cytofix/CytoPerm eBiosciences) then stained using mAbs 
specific for IL-2, IL-10, IL-17, IL-22, IL-23, IFN-and TNF- (BioLegend, San Diego, 
USA).  7AAD was used to exclude dead cells from the analysis.  Cells were acquired on a 
BD Canto II (BD, Bioscience, San Jose, USA). Analysis was performed using Flowjo (Tree 
Star Inc., USA). 
LIVER BIOPSIES 
Tru-cut liver biopsies were performed on NMP and CS grafts at the end of preservation 
(pre-reperfusion) and 60 min following reperfusion (post-reperfusion, Figure 1. Panel A). A 
2-3-mm portion of the needle biopsy liver cylinder was immediately snap frozen in liquid 
nitrogen and transferred to -80C degree freezer. The remaining cylinder was formalin fixed 
and paraffin embedded (FFPE).  
LIVER TISSUE RNA EXTRACTION AND PROCESSING 
For total RNA extraction, cryopreserved liver tissue samples were homogenized in 
TRIzol reagent (Invitrogen) using a pestle and nuclease-free 1.5-ml reaction tubes (Ambion). 
Total RNA was then extracted following the manufacturers guidelines, and quality was 
assessed with the Agilent 2100 Bioanalyzer (Agilent Technologies).  
LIVER TISSUE MICROARRAY GENE EXPRESSION ANALYSIS 
Microarray data were analyzed using Illumina microarrays: expression data were 
computed using BeadStudio data analysis software (Illumina) and subsequently processed 
employing quantile normalization using the Lumi bioconductor package. Next, a step of 
conservative probe-filtering was used to excluding those probes with a detection P value 
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greater than 0.05 in all samples which resulted in the selection of a total of 27084 probes 
from the original set of 29377. Differential expression was assessed by using linear models 
and empirical Bayes moderated t-statistics. Linear Models for Microarray Analysis (LIMMA) 
R-package software was used for the analysis of gene expression microarray data. Group 
comparisons and determinations of false discovery rates (FDR computation using Benjamini-
Hochberg procedure) were performed (13). All liver tissue microarray data discussed in this 
publication have been deposited in NCBI’s Gene Expression Omnibus (GSE112713). To 
further explore the functional relationships between groups we dissected the molecular 
pathways contained in the microarray differential gene expression data set employing both 
Gene Set Enrichment Analysis (GSEA) using canonical pathways C2 geneset collection (14).  
qPCR on liver tissue 
qPCR was conducted employing the ABI 7900 Sequence Detection System and 
TaqMan LDA microfluidic plates (Applied Biosystems). DNA was removed from total RNA 
preparations using Turbo DNA-free DNAse treatment (Ambion), and RNA was then reverse 
transcribed into cDNA using the High-Capacity cDNA Reverse Transcription Kit (Applied 
Biosystems). To quantify transcript levels, target gene Ct values were normalized to the 
housekeeping gene (GAPDH) to generate ΔCt values. 88 genes were analysed in total.  
IMMUNOHISTOCHEMISTRY STAINING AND HISTOLOGICAL IMAGING 
Pre- and post-reperfusion biopsies were fixed in 10% buffered formalin, paraffin 
embedded, then cut into 4 µm-thick sections fixed to microscope slides. Tissue sections were 
stained with routine haematoxylin and eosin (H&E), as well as immunohistochemical (IHC) 
staining for myeloperoxidase (MPO), using a fully automated IHC Leica BOND-MAX 
immunostainer (Leica Biosystems, Newcastle, UK), and each biopsy was scored using 
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standard criteria (see supplementary S1). The signal was detected with a Leica Bond Polymer 
Refine Detection kit (Novocastra, Newcastle, UK). The antibodies used were obtained from 
Abcam Plc. (Cambridge, UK).  
STATISTICAL ANALYSIS 
Statistical analysis was performed using GraphPad Prism 5.0 (GraphPad Software, San 
Diego, USA). Data were presented as mean values +/- SEM, and statistical significance was 
determined using the Mann Whitney U test when comparing two unpaired/unmatched 
groups; the Kruskal-Wallis test when comparing multiple unpaired/unmatched groups with 
post hoc Dunns multiple comparison tests; and the Two-Way ANOVA (Ordinary) with 
Sidak’s multiple comparisons test when comparing multiple unmatched groups with more 
than one grouping variable. All tests carried out were nonparametric. Statistical significance 
was considered when: *P ≤ 0.05.  
 
Results 
CLINICAL DATA SHOWED REDUCED IRI 
Consistent with the clinical data derived from two clinical trials (10,11), peak AST 
within 7 days was significantly lower in the NMP group compared with the CS group 
(p<0.01) (Table 2) . Additionally, peak INR within 7 days was lower in NMP group 
compared to CS group (p=0.07). The other biochemical post-operative parameters that 
include alkaline phosphatase (ALP) and total bilirubin together with post-transplant clinical 
parameters such as the days of ITU stay, the rates of acute rejection and one year graft and 
recipient survival, which were comparable between the two groups. The data are shown in 
Tables 1 and 2.   
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NMP UP-REGULATED TISSUE REGENARATION GENES AND DOWN-
REGULATED PRO-INFLAMMATORY GENES 
In order to gain a global picture of how NMP protects hepatocytes and maintains 
allograft function, we assessed the gene expression profiles of NMP (n=11) and CS (n=11) 
liver biopsies taken after preservation (pre-reperfusion) and after transplantation (post-
reperfusion) by using microarray analysis (Figure 1. Panel A).  
19,416 genes were assessed with a cut-off for significance of 1.5-fold change and of 
<25% false discovery rate (FDR). We assessed the gene expression changes that occurred 
from pre-reperfusion to post-reperfusion for both NMP and CS liver tissues; we also assessed 
the unique genes changed in each cohort and the changes common to both. For both NMP 
and CS there were more genes down regulated (CS: 3550; NMP: 2402; Both: 2212) than up-
regulated post-reperfusion (CS: 256; NMP: 306; Both: 243). Among those 306 up-regulated 
genes in NMP there are genes that relate to tissue regeneration and platelet function, but not 
many genes which relate to immune cell functions. In contrast, there was a high 
representation of immune-related genes within the 256 up-regulated in CS, in particular pro-
inflammatory cytokines and genes involved in humoral immunity, neutrophil chemotaxis and 
platelet function. A similar functional representation was seen for down-regulated genes in 
the 2402 NMP genes and the 3550 CS genes. The genes that commonly changed in both 
NMP and CS contained a moderate number of immune-related genes; both pro- and anti-
inflammatory, neutrophil- and coagulation-related genes, and those involved in tissue 
regeneration (Figure 1. Panel B).  
We then investigated the differences in gene expression between NMP and CS at the 
time of pre- and post-reperfusion. The differences were greater at the pre-reperfusion stage 
(568 up- and 574 down-regulated genes in NMP relative to CS) compared to those in post-
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reperfusion stage (213 up- and 219 down-regulated genes in NMP relative to CS) (Figure 1. 
Panels C and D). To investigate what biological pathways are altered due to these changes in 
gene expression, we analysed the gene data using GSEA canonical pathway analysis using a 
cut-off for significance of <25% false discovery rate (FDR). NMP showed a down regulation 
of 123 pathways pre-reperfusion and 74 pathways post-reperfusion relative to CS (see 
supplementary S2 and S3). Pathways down-regulated in pre-reperfusion included “allograft 
rejection”, “graft versus host disease”, 7 platelet/coagulation pathways, and 16 immune 
pathways including “TH1TH2”, “IFNG signalling”, “PD1 signalling”, “IL-2”, “IL-12”, “IL-
6”, and “CCR5”. Pathways down-regulated in post-reperfusion included 3 
platelet/coagulation pathways and 12 immune pathways including “IL-17”, “neutrophils”, 
“IFNFLAM”, “BCR”, “integrin 2”, “leukocyte transendothelial migration”, and “PD1 
signalling”. 
In order to validate our findings from the microarray analysis we performed 
quantitative PCR (qPCR) on 88 genes that were either up- or down-regulated in NMP livers 
relative to CS livers; including genes involved in stress response, growth and regeneration, 
apoptosis, metabolism, and immune responses.   
We also investigated a number of IRI-related genes previously described by us (5). The 
majority of genes showed a clear differential expression between livers that were maintained 
by NMP and those stored using CS. A number of genes involved in response to stress and cell 
death or apoptosis were up-regulated in CS but not in NMP livers post-reperfusion (Figure 2. 
Panel A), examples of which include the genes for thrombomodulin (THBD) and IFN-γ 
(IFNG) (Figure 2. Panel B). NMP livers showed a significant up-regulation of genes involved 
in immune-trafficking compared to CS in both Pre- and Post-reperfusion stages; such genes 
included CXCL9, CXCL10, and CXCL11 (Figure 2. Panel B).  
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CD4posCD25highCD127negFOXP3pos REGULATORY T CELLS WERE MORE 
ABUNDANT IN NMP GRAFTS 
We have previously shown that intrahepatic lymphocytes obtained through liver 
perfusion are representative of liver-resident lymphocytes (12). We assessed the impact of 
NMP on the proportions of HMC compared to CS using flow cytometric analysis of liver 
perfusates collected after each respective preservation (pre-reperfusion, Figure 1. Panel A).  
Viability of HMC from both NMP and CS liver grafts was constantly higher than 95%. 
Approximately 9 to 50 x 106 living HMC were isolated from NMP liver grafts (n = 8) and 40 
to 60 x106 from CS grafts (n = 21). 
The proportion of hepatic CD3negCD19pos B cells, CD3posCD4pos T cells and 
CD3posCD56pos NKT-like cells were comparable amongst NMP and CS grafts. The 
proportion of CD3negCD56pos NK cells tended to be higher in CS than in NMP grafts 
(p=0.08) (Figure 3. Panels A and B).  By contrast, the proportion of CD3posCD8pos T cells 
(41.97%16.03 versus 18.6%8.2, p=0.0005) (Figure 3. Panel B) and 
CD4posCD25highCD127negFOXP3pos regulatory T cells (Tregs) (4.36%3.27 versus 1.9%1.8, 
p=0.0156) were significantly higher in NMP than in CS liver grafts (Figure 3. Panel C).  
NMP GRAFTS CONTAINED FEWER PRO-INFLAMMATORY CYTOKINE-
PRODUCING T CELLS THAN CS GRAFTS 
Intrahepatic T cells are a rich source of T helper and regulatory cytokines; chemical 
mediators capable of promoting inflammation, cellular regeneration, fibrosis, or immune 
tolerance. Using flow cytometry, we next assessed the effect of NMP on Th1 (IL-2, IL-17, 
IFN-γ), Th2 (IL-4) and Treg (IL-10 and TGF-β) cytokine production by intrahepatic CD4pos 
and CD8pos T cells (Figure 3. Panels D and E). NMP had significantly lower proportions of 
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CD4pos T cells producing IL-4 (p<0.05), IL-2 (p<0.001), IFN-γ (p<0.05) and IL-17 
(p<0.0001). There was no change in the production of the regulatory cytokines IL-10 (Figure 
3. Panel E) or TGF- (data not shown). Furthermore, NMP significantly decreased the 
proportions of CD8pos T cells producing IFN-γ (p<0.001), while modest reductions in IL-17 
were also observed. There were no changes in IL-2 production by CD8pos T cells after NMP 
(Figure 3. Panel E). 
DONOR ICU-STAY INFLUENCED T CELL FUNCTION IN NMP GRAFTS 
We then sought the associations between HMC function and allograft functions. 
Among HMC collected after NMP, there was a positive correlation between the days of 
donor ICU stay and the frequency of IL-17 producing CD4pos T cells (R2=0.69, p=0.01) 
(Figure 3. Panel F). There was no correlation between donor infection status, BMI and/or 
fatty liver score and HMC functions. 
COLD ISCHEMIA TIME WAS THE MAIN FACTOR INFLUENCING ALLOGRAFT 
FUNCTION  
In the setting of CS, there was a positive correlation between peak AST levels and the 
duration of cold ischemia (R2=0.34, p=0.0071), and a negative correlation between IL-10 
producing CD4pos T cells and duration of cold ischemia (R2=0.56, p=0.01) (Figure 3. Panel 
F).  
Although we did not observe a correlation between the frequency of IFN--producing 
CD8pos T cells and peak AST levels as reported by us in 2015 for CS grafts, after combining 
the CS and NMP cases, there was a positive correlation between the frequency of IFN- 
producing CD8pos T cells and peak AST levels (R2=0.4, p<0.05) (data not shown). We did not 
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observe any correlations with donor parameters, including age, BMI, days of ICU stay, 
infection status and fatty liver score.  
REDUCED NEUTROPHIL INFILTRATION AND CELL DEATH FOLLOWING 
NMP 
By performing tissue staining on biopsies collected pre- and post-reperfusion, we 
sought evidence to support the hypothesis that reduced IRI is the consequence of NMP (H&E 
staining not shown), since both pre- and post-reperfusion biopsies showed fewer 
apoptotic/necrotic cells in NMP compared to CS, although apoptosis/necrosis was increased 
in post-reperfusion biopsies in both NMP and CS conditions compared to pre-reperfusion 
(Figure 4. Panels A and B, Figure 5. Panel A).  
The number of neutrophil clusters tended to be lower in pre-reperfusion compared with 
post-reperfusion biopsies in both NMP and CS (Figure 5. Panel B). However, NMP livers 
showed lower numbers of clusters compared with CS livers in both pre- and post-reperfusion 
stages (Figure 5. Panel B). 
We also evaluated neutrophil infiltrate by MPO single epitope staining. The NMP 
group had significantly fewer of MPOpos cells in the liver lobules, in both pre- (p = 0.0002) 
and post- (p = 0.036) reperfusion biopsies compared to CS allografts, although the reduction 
of MPOpos cell staining was more pronounced at the pre-reperfusion stage (Figure 5. Panel 
C).  
STEATOSIS STATUS DID NOT CHANGE AFTER NMP  
Finally, we assessed the impact of NMP on the fatty content of the liver grafts. We did 
not observe significant differences in terms of steatosis, both small and large droplet (data not 
shown), between pre- and post-reperfusion biopsies.  
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DISCUSSION  
NMP has emerged as an effective tool for liver graft preservation, since it has the 
ability of avoiding cold ischemia and reducing IRI sequelae as shown in a phase I clinical 
trial (10) and a recent randomized multicentre controlled clinical trial (11). It is assumed that 
the beneficial effect of NMP is the consequence of a combination of factors, including 
perfusion at body temperature, oxygenation, and the addition of nutrients and anti-oxidants, 
which maintain the liver as closely as possible to physiological conditions. In the current 
study, we showed that the beneficial effect of NMP was derived from the combination of the 
following: maintaining liver metabolism, inhibiting inflammation and reducing cell death.   
We have confirmed that NMP did have an impact on graft quality by reducing IRI 
sequelae in liver grafts, in the form of lower peak AST levels in the first postoperative week 
compared to those receiving CS grafts. AST is a well-defined surrogate marker for long term 
graft function and survival (15). This is consistent with the previously reported data (10,11), 
confirming that NMP is indeed able to reduce the degree of IRI. Although the impact of NMP 
on one-year graft and patient survival was comparable between NMP and CS groups, longer 
period of follow-up would be more desirable.  
By collecting liver tissues at two key time points, pre-reperfusion (post NMP) and post-
reperfusion, we assessed the gene expressing patterns in three ways: 1) differences occurred 
from pre-reperfusion to post-reperfusion for both NMP and CS liver tissues; 2) differences 
between NMP and CS at pre- and post-reperfusion; 3) the unique genes changed in each 
cohort and the changes common to both. 
 When NMP and CS were assessed separately in terms of the gene expression changes 
that occurred post-reperfusion relative to pre-reperfusion, NMP liver showed significant gene 
activity in the areas of growth, metabolism and tissue repair, while CS livers showed more 
immune-related gene activity post-reperfusion. In order to directly compare NMP to CS, the 
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differences in gene-expression profiles were assessed in both pre- and post-reperfusion 
biopsies. NMP showed the greatest difference from CS at the pre-reperfusion stage, in 
particular, the down-regulation of pathways such as “allograft rejection”, “graft versus host 
disease”, and “platelet/coagulation”, we believe that the alterations in these pathways 
possibly contributed to the beneficial effect of NMP to minimise IRI. It is worth pointing out 
that some of the pathways down-regulated in NMP have been defined previously as being 
involved in inflammation in the setting of transplantation (16), such as “IFNG signalling” 
(17), “IL-2” (18), “IL-6” and “IL-12” (19). In combination with “PD1 signalling” (20), the 
down-regulation of these pathways could suppress the initiation of IRI and reduce cell 
apoptosis. More importantly, “PD1 signalling” was continuously down-regulated post-
reperfusion, along with several others with known roles in IRI, including 
“platelet/coagulation” (21), “neutrophils” (22) and ‘IL-17” (23). 
In addition, both NMP and CS promoted up-regulation of pathways including 
“differentiation”, “regeneration” and “healing”. Taking together the fact that NMP down-
regulated inflammation, the overall impact of NMP should favour the preservation of grafts 
in good quantity by minimizing inflammatory and cell death events associated with IRI. 
While confirming the alterations of 88 key genes following NMP by qPCR, we further 
evaluated the expression levels of individual genes (Figure 2. Panel B). Of these genes, the 
CXC chemokine family genes, CXCL9, CXCL10 and CXCL11, known to elicit their 
chemotactic functions by interacting with the chemokine receptor CXCR3 (24), changed their 
expression in synchrony. Their levels were significantly higher in NMP tissues than in CS at 
both time points, although CXCL11’s level was higher at post-reperfusion only. It is known 
that IFN- induces the expression of CXCL9 (25), its up-regulation was not hindered by the 
reduced levels of IFN- in NMP grafts. The CXC family was recently shown in mouse to 
have a novel role in converting CD4 T effectors into CD4/CD8 double negative regulatory T 
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cells and their migration to the liver (26), hence this pathway might contribute to the reduced 
IRI. 
Next, we tested the hypothesis that inhibited gene expression defined by microarray 
could be linked to their translation status, i.e. cytokine secretion by donor derived T cells to 
inhibit inflammation. We collected hepatic lymphocytes at the end of NMP, the same time 
point when pre-reperfusion liver biopsies were taken. Therefore, we were able to evaluate the 
impact of NMP directly on donor hepatic lymphocytes, the major player in graft rejection  
and tolerance induction (27) by comparing with lymphocytes collected from CS grafts. We 
observed reduced numbers of pro-inflammatory cytokines IFN- and IL-17 producing CD4pos 
and CD8pos T cells which are known to be involved in the process of IRI (28, 29). In 
conjunction with reduced AST levels in recipients, it is logical to speculate that down-
regulated pathways “IFNG signalling” and “IL-17” contribute to the overall impact of NMP 
in reducing IRI. The other possibility is that the altered ratio of Tregs to T effectors provides 
a counterbalance for the tissue damaging effects of IL-17 producing T effectors in NMP 
grafts. This assumption is based on an unexpected finding that CD4posCD25highCD127neg 
FOXP3pos regulatory T cells (Tregs) pool was enlarged following NMP. In the NMP liver 
grafts, Tregs were about 2.3 folds compared to those in CS livers, indicating that preservation 
using NMP was able to retain or even increase Treg number. It is well recognised that Tregs 
could reduce IRI (30). In view of the fact that the liver contains approximately 1010 
lymphocytes of which two thirds are T cells, and donor derived lymphocytes are constantly 
released into the recipient’s circulation and could still be detected even 30 years after 
engraftment (31), donor-derived Tregs are likely to be involved in the process of induction of 
graft acceptance. Comparing the attempt of generating ex vivo Tregs from recipients pre-liver 
transplantation, with target number of 10 x 106 /kg recipient body weight (The ONE study 
UK Treg trial: https://clinicaltrials.gov/ct2/ show/NCT02129881), donor derived Tregs 
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outnumber those derived from the recipient. Once the outcome of this trial is released, further 
comparison of the efficacy of Tregs derived from either donors or recipients can be carried 
out.    
Regarding the immunoregulatory cytokine IL-10, we observed a negative correlation 
between the frequency of IL-10 producing CD4pos T cells and cold ischemia time, indicating 
that CS could influence HMC immunoregulatory function in contrast with NMP, which has 
the potential to enhance the production of IL-10 through an enlarged Treg pool.  
The other important finding is that down-regulated genes in “neutrophils” pathways did 
lead to a significant reduction in neutrophil infiltration in NMP grafts. This reduction was 
observed in both pre- and post-reperfusion liver tissues. Giving the important role played by 
platelets on IRI and inflammation (32), we believe that the reduction in “platelet/coagulation”  
gene expression may have contributed to the reduced IRI in NMP recipients, and we intend to 
investigate this further in future studies.  
Attenuation of neutrophil infiltration in pre-reperfusion biopsies in NMP livers is of 
interest. Leucocyte infiltration in DBD donors is well documented as results of the systemic 
inflammatory response associate with brain death (33). It is possible that NMP reduces 
neutrophil levels by the fact that there is circulation during the preservation time and possibly 
to an anti-inflammatory hepatic environment, discussed earlier. More work is necessary to 
elucidate neutrophil movements during NMP and it’s impact on graft outcome.  
Research in recent years has provided rich data to elucidate the interaction between 
platelets and neutrophils (34), in the context of liver transplantation, by forming complexes 
platelets and neutrophils jointly drive IRI in the liver (35). Therefore, reducing neutrophil 
infiltration will lead to controlling the formation of this complex and ameliorating IRI.  
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One of the key goals of NMP is to improve the quality of marginal liver grafts which 
are currently labelled as unusable and rejected by all liver transplantation centres due to their 
high fat content (>60%) (36), we also assessed whether the fat content could be reduced by 
NMP. However, our investigation was restricted by the fact that all the liver grafts included 
in the current study were usable and the majority of them contain very low to no fatty content 
(Table 1). No change in fat content was seen following NMP. Recently, Liu Q et al (37) 
assessed lipid metabolism and function of discarded human livers with steatosis (up to 
33.3%) after 24-hour NMP. When the period of NMP finished, the fatty content was almost 
unchanged, indicating that NMP is unlikely to impact on liver fat content when it is at an 
acceptable level and only a high proportion of fat, i.e., >60% should be treated by NMP and 
assessed.  
In conclusion, the data of the current report have provided mechanistic support to the 
clinical application of NMP. By minimising inflammation, cell death and, promoting liver 
regeneration and healing, NMP might be an ideal tool to rescue those currently discarded 
marginal allografts, including DCD, and potentially to increase the donor pool. 
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Figure legends 
Figure 1. Microarray showing gene expression profiles of NMP liver grafts compared to 
CS grafts indicating reduced inflammation and increased regeneration. A. Schematic 
diagram showing the timing of liver-tissue biopsies, the first time point was after a period of 
preservation by either CS or NMP right before reperfusion in the donor (pre-biopsy), and the 
second time point was 60 minutes after reperfusion (post biopsy); B. Venn diagram showing 
the changes in gene expression (up and down-regulated) in post-reperfusion relative to pre-
reperfusion biopsies, as analysed by the R/Bioconductor package GO stats. In both NMP and 
CS, the number of genes significantly altered were displayed along with a list of the 
functional categories most represented by these genes; C and D. Volcano plots showing the 
changes in expression (up and down) of all the genes obtained by microarray analysis, in 
NMP liver grafts relative to CS liver grafts at the pre-reperfusion stage (C) and post-
reperfusion stage (D). The grey area denotes significantly changed genes, the number of 
those genes was displayed, and examples were displayed with arrowed labels. Significance 
was decided by a cut-off of 1.5-fold change and of <25% FDR. CS: cold storage; NMP: 
normothermic machine perfusion; FDR: false discovery rate. 
Figure 2. qPCR confirming gene expression findings by microarray. A. A heat map 
showing the expression levels of 88 genes, tested by qPCR from NMP and CS liver biopsies 
taken pre- and post-reperfusion (11 cases per group), as well as a qPCR assay control; Red 
denotes up-regulated expression and green is down-regulated expression; genes grouped by 
function were outlined by the dashed lines. B. Ct values (inversely proportional to gene 
levels) for 8 genes in liver biopsies from: Pre CS and Pre NMP (pre-reperfusion), Post CS 
and Post NMP (post-reperfusion);; groups were compared using Kruskal-Wallis test (* P ≤ 
0.05 and **P ≤ 0.01).    
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Figure 3. Hepatic lymphocytes from NMP liver grafts exhibiting an anti-inflammatory 
phenotype. A. Representative flow cytometry density plot showing T cell markers of CD4 
and CD8 expression on T cells from HMC. Frequencies of CD4pos T, CD8pos T, B, NK, NKT-
like cells (B), and Treg cells (C) within HMC from NMP and CS livers pre-reperfusion; D. 
Representative flow cytometry contour plot showing IFN- expression by T cell from HMC 
(right) and fluorescence-minus-one (FMO) control with HMC stained with all antibodies 
except anti-IFN-; E. Frequencies of IL-4, IL-10, IL-2, IFN- and IL-17 producing CD4pos 
and CD8pos T cells within HMC from NMP and CS livers; F. Linear regression analysis from 
left to right showing the positive correlation between the percentages of IL-17 producing 
CD4pos T cells in NMP livers and the days of donor staying in intensive care unit (ICU); a 
positive correlation between the peak levels of recipient aspartate aminotransferase (AST) 
and cold ischemic time (CIT); and a negative correlation between percentages of IL-10 
producing CD4pos T cells in CS livers and CIT. CS: cold storage; NMP: normothermic 
machine perfusion; HMC: hepatic mononuclear cells; FS: forward scatter.; groups were 
compared using Two-Way ANOVA with Sidak’s multiple comparisons test (* P ≤ 0.05 and 
***P ≤ 0.001).    
Figure 4. Reduced immune cell infiltrates in NMP liver tissue. Representative 
micrographs of MPO (A) stained biopsies from NMP and CS liver grafts at pre- and post-
reperfusion stages, showing more disseminated immune cell infiltrate in CS compared to 
NMP livers, which is identified as neutrophils by MPO immunohistochemical staining.  
Neutrophil infiltration in the hepatic lobules was reduced in NMP liver grafts. Representative 
micrographs showing MPO staining in the hepatic lobules (B) of biopsies from NMP and CS 
liver grafts at pre- and post-reperfusion stages. High power fields were randomly selected for 
each case from the lobular region. MPO: myeloperoxidase. 
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Figure 5. IRI was reduced in NMP liver grafts compared to CS. A. Percentage of cases 
with cell death, apoptosis (score 1 or 2) and necrosis (score 3, 4, or 5) from NMP and CS 
liver grafts at both pre- and post-reperfusion stages. B. Percentage of cases with absence 
(score 0) or presence of neutrophil clustering (score 1 – 5) from NMP and CS grafts at both 
pre- and post-reperfusion stages. C. Proportions of MPOpos cells in the hepatic lobule from 
NMP and CS grafts at both pre- and post-reperfusion stages. IRI: ischemia-reperfusion 
injury; groups were compared using Kruskal-Wallis test (* P ≤ 0.05, ***P ≤ 0.001).   
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